Definium Therapeutics (DFTX) Interest & Investment Income (2023 - 2026)

Definium Therapeutics (DFTX) has reported Interest & Investment Income for 4 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income rose 42.09% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $12.0 million (down 2.85% YoY), while the FY2025 annual figure was $11.0 million, down 5.17% from the prior year.
• Interest & Investment Income eased to $3.5 million in Q1 2026 per DFTX's latest filing, from $3.5 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $3.5 million in Q3 2024 and bottomed at $1.3 million in Q4 2023.
• Historically, Interest & Investment Income has averaged $2.4 million across 4 years, with a median of $2.4 million in 2025.
• Annual changes were most pronounced in 2024 — Interest & Investment Income surged 143.97% — and 2025, when it slumped 35.5%.
• Definium Therapeutics' Interest & Investment Income stood at $1.3 million in 2023, then soared by 143.97% to $3.3 million in 2024, then increased by 6.47% to $3.5 million in 2025, then slipped by 0.97% to $3.5 million in 2026.
• Business Quant data shows DFTX's Interest & Investment Income at $3.5 million in Q1 2026, $3.5 million in Q4 2025, and $2.3 million in Q3 2025.